Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference

This image opens in the lightbox

News provided by

Northwest Biotherapeutics

25 Jan, 2019, 14:17 GMT

Share this article

Share toX

Share this article

Share toX

Focus on Complexity and Variability of Solid Tumors, and How DCVax®-L Addresses Them

BETHESDA, Md., Jan. 25, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented at the Phacilitate Leaders World 2019 Conference in Miami, Florida. The slide deck from this presentation can be found on the Company's website at www.nwbio.com.  

Ms. Powers noted that although immune therapies have made great progress on blood cancers, the key challenge for immune therapies lies in treating solid tumors because solid tumors comprise at least 80% of all cancers and they are much more complex and variable. Ms. Powers noted that there is extensive variation (i) among solid tumor cancers, (ii) between patients with the "same" cancer, (iii) within a single patient over time and (iv) even within a single solid tumor in a single patient at a single moment in time.  (Biopsies taken from different locations within a single tumor can yield different results.)  Ms. Powers described how DCVax®-L is tailored to address these challenges.

Focusing on Glioblastoma brain cancer, Ms. Powers noted that the standard of care was established 14 years ago in 2005, when chemotherapy was approved to be added to surgery and radiation based upon adding 10 weeks of survival. She reviewed the enormous expansion of scientific knowledge in the years since then, with extensive knowledge today about the disease and relevant patient characteristics – but without this expanded scientific knowledge translating into any meaningful improvement in median survival times of patients. Median survival was about 14.6 months in 2005, and today is still only about 15-17 months.

Ms. Powers described the results of an academic review of the clinical trials for Glioblastoma which were conducted between 2005 and 2016:  417 clinical trials were conducted, involving approximately 32,000 patients; only 16 of those trials were Phase 3 trials, and only one of the Phase 3 trials reached a positive result extending patient survival. (That trial involved a medical device.) [1]

It is noteworthy that, contrary to the approach taken by DCVax-L, these failed cancer treatments  typically used a "silver bullet" approach: a single active agent aimed at just one target on the cancers or just a few targets (e.g., bi-specific, tri-specific or a half-dozen or so targets).  It is a real question whether such narrow approaches are realistic against the enormous complexity and variability of solid tumors. 

Ms. Powers described the large publicly funded Cancer Genome Atlas project that analyzed and profiled solid tumors, starting with Glioblastoma. Their initial findings, published in 2008, reported that analysis of 91 tumor tissue samples, looking at just 601 genes, found 453 mutations in 223 unique genes. [2]  Their broader findings, published in 2013, reported that analysis of 291 tumors found 21,540 mutations, including a variety of different types of mutations. [3] 

Building upon the Cancer Genome Atlas findings, the NIH commented that "it is now evident that glioblastoma growth is driven by large signaling networks that have a functional redundancy that permit adaptation of the tumor in response to targeted molecular treatments". [4]  Ms. Powers pointed out that such redundancy and adaptation provide escape routes that help tumors escape from treatments. 

The Company believes that a "silver bullet" treatment approach is unlikely to be effective against such enormous variation in tumors and such escape mechanisms.  Ms. Powers noted that, in addition to Glioblastoma, other types of solid tumors also involve extensive variations and corresponding treatment challenges.  To date, only limited numbers of patients (e.g., 5-30% for various cancers) have been reported to respond to immune therapies for solid tumors, including checkpoint inhibitors.  In light of the extensive variation among solid tumors, a patient's version of a cancer may or may not express a particular single target or couple of targets.

Ms. Powers explained that the approach taken by the Company's DCVax therapies uses Nature's system and is the opposite of a "silver bullet" approach:  i.e., many active agents against many targets, rather than a single active against just one or a few tumor targets.  DCVax-L is designed to achieve this through 3 key characteristics:

  • Uses the master cell of the immune system:  dendritic cells (DCs)
    Mobilizes the overall immune system, both T cells and other active agents
    DCs have a large multiplier effect, mobilizing both large numbers of T cells and diverse T cells (diverse both as to tumor targets and as to types of T cells – helper T, killer T, etc.) 
  • Is fully personalized
    Avoids Russian roulette at the outset, as to whether the patient's tumor expresses the treatment target -- fits the patient's version of the cancer.
  • Uses ALL tumor antigens (i.e., targets), not just one or a few targets
    Minimizes tumor escape after treatment. (When treatments target just one or a few antigens, tumors stop expressing those.)

The Company has been testing this approach in its Phase 3 trial of DCVax-L for newly diagnosed Glioblastoma, and is now working on various stages of preparations towards completion and unblinding of the trial.  As previously reported, the blinded interim data (i.e., data from the treatment and placebo arm of the trial combined) through October 2018 indicate that:

  • Median survival of all 331 patients in the trial, from surgery, was 23.1 months.
  • The top 100 patients – 30% of all patients in the trial – have a Kaplan Meier median survival of 58.4 months.
  • Apparent survival extensions are seen across the range of patient demographics and characteristics, both in patients with favorable prognostic factors and patients with unfavorable prognostic factors (age, physical condition, number of immune cells, full or partial surgical removal of tumor, status of MGMT gene, etc.)
  • The safety profile has been excellent: with the DCVax-L product administered over 2,000 times, only 7 of the 331 patients (2%) experienced any "serious adverse event" that was deemed at least "possibly related" to the treatment. DCVax-L does not involve any hospital inpatient or ICU stays, as some other immune therapies do, and does not require additional drugs to manage side effects.

The presentation concluded with a review of the practicality of DCVax-L for commercialization.  Ms. Powers noted that all doses for a patient are manufactured in a single batch and stored frozen, that this enables repeated dosing of patients over a multi-year period, and that such doses are all "off the shelf" after the initial manufacturing.

[1]  Neuro-Oncology. 20(8) 1034-1043, 2018
[2]  Nature. 2008 Oct 23; 455(7216):1061-8
[3]  Cell. 2013 Oct 10; 155(2): 462–477
[4]  NIH News Release, October 28, 2013, Genomic Understanding of Glioblastoma Expanded  

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe.  The Company has broad platform technologies for DCVax® dendritic cell-based vaccines.  The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease."  The Company is also pursuing a Phase I/II trial with DCVax®-Direct for all types of inoperable solid tumor cancers.  It has completed the 40-patient Phase I portion of the trial, and is preparing for Phase II portions.  The Company previously conducted a Phase I/II trial with DCVax®-L for metastatic ovarian cancer together with the University of Pennsylvania. 

Disclaimer                 

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  We cannot guarantee that we will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statements.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to complete its clinical trials on a timely basis, uncertainties about the clinical trial results and data, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings.  Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo - https://mma.prnewswire.com/media/783522/NW_Bio_logo_Logo.jpg

Related Links

http://www.nwbio.com

Modal title

Also from this source

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid ...

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Trade Show News

Trade Show News

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.